What is VYNE's current stock price?

VYNE (VYNE Therapeutics Inc.) is currently trading at $0.67 with a market cap of $11.2M.

What sector is VYNE Therapeutics Inc. in?

VYNE Therapeutics Inc. (VYNE) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is VYNE a good stock to buy?

Analysts have a Hold consensus on VYNE with a price target of $5.75. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

VYNE VYNE Therapeutics Inc.

Healthcare

$0.67-0.96%ClosedMarket Cap: $11.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.17

P/S

24.64

EV/EBITDA

0.55

DCF Value

$0.47

FCF Yield

-230.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

98.7%

Operating Margin

-5367.6%

Net Margin

-4726.2%

ROE

-69.6%

ROA

-82.9%

ROIC

-98.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$86.0K	$-3.6M	$—
Q4 null	$130.0K	$-4.8M	$—
FY null	$570.0K	$-26.5M	$—
Q3 null	$169.0K	$-7.3M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$5.75

Target (Median)

$5.75

Target Range

$5.75 - $5.75

0 Strong Buy1 Buy2 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Neutral

2025-07-30

Trading Activity

Insider Trades

View All

Zeronda Tylerofficer: CHIEF FINANCIAL OFFICER

SellThu Apr 02

Stuart Iainofficer: CHIEF SCIENTIFIC OFFICER

SellThu Apr 02

Harsch Mutyaofficer: CHIEF LEGAL OFFICER AND GC

SellThu Apr 02

Domzalski Daviddirector, officer: PRESIDENT AND CEO

SellThu Apr 02

Zeronda Tylerofficer: CHIEF FINANCIAL OFFICER

SellMon Jan 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.00

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Peers

AIM